'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'
Adding a new dimension to its business, the Mukesh Ambani-led Reliance Life Sciences announced on Thursday its partnership with US-based global investment management firm, MPM Capital LP.
Mukesh Ambani's privately held biotech research company, Reliance Life Sciences, will soon diversify to take up biofuel production in a major way. Industry sources said the facilities might require an investment of Rs 150-200 crore (Rs 1.5 billion to Rs 2 billion). One hectare of land yields about a tonne of crop, so RLS will need to cultivate about one lakh hectares of land, they say. The majority of investments go into sourcing raw material, they say.
Reliance Life Sciences is planning to invest at least Rs 1,000 crore (Rs 10 billion) to set up hospitals in the country's metros and dispensaries in small towns.
Stem cell research major GlobalStem in talks for a strategic alliance.
This first-of-its-kind-in-India centre is fully funded by Reliance Foundation and includes a negative pressure room that helps in preventing cross-contamination and helps control infection. All beds are equipped with the required infrastructure, biomedical equipment such as ventilators, pacemakers, dialysis machines, and patient monitoring devices.
An investigation by government agencies is under progress into the alleged violation of rules in investments made by Singapore-based Biometrix Marketing, a Reliance Industries (RIL) group firm.
Indian drug companies, which have introduced copies of biotechnology drugs in the country, are bullish over the marketing prospects of 'biogenerics' after patents expire in developed markets. Experts say Indian companies may not repeat the success they achieved in selling generic medicines in biogenerics. The cost of clinical trials and the absence of substitutability will ensure that only those with deep pockets to launch such products globally will succeed, they feel.
While company executives refused to divulge further details, industry sources said that Reliance has earmarked a huge area in the SEZ for the project.
Reliance Pharmaceuticals, the proposed pharmaceutical manufacturing company promoted by Mukesh Ambani's Reliance Life Sciences, will soon rope in a consultant to give final shape to the project, slated to take off within two years.
Competing with established biotech companies in India such as Wockhardt, Biocon and Reliance Life Sciences, small biotech companies such as Zenotech, BV Biocorp and Intas Biopharma are likely to emerge as major players in biogeneric drugs.
Mukesh Ambani-promoted biotech venture Reliance Life Sciences is close to acquiring a US company for nearly $1 billion (Rs 4,500 crore).
Mukesh Ambani-controlled Reliance Life Sciences is to invest $63.2 million for a controlling stake in UK's biopharmaceutical company GeneMedix Plc.
Responding to another question, Choubey said that the phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd, and now their immunogenicity testing is in progress. Their phase II clinical trials are ongoing.
Garima Bharucha, 39, from Mumbai shares her inspiring fitness journey and the lessons she learned along the way.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances